# US 12,110,344 B2 · Antibodies that bind to cis and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,110,344 B2 - Document ID: US12110344B2 - Status: Granted - Kind: B2 - Application number: 18/515,714 - Filed: 2023-11-21 - Published: 2024-05-23 - Granted: 2024-10-08 - Earliest claimed: 2022-11-21 - Assignees: Dianthus Therapeutics Opco, Inc. - Applicants: Dianthus Therapeutics Opco, Inc. - Inventors: Vahe Bedian; Charles A. Omer - Web page: https://patentgrep.com/patent/US12110344B2 ## CPC - C07K 16/40: against enzymes - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - C07K 16/18: against material from animals or humans - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 2039/505: {comprising antibodies} - A61K 2039/54: {characterised by the route of administration} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Embodiments that are provided for herein relate to antibodies and compositions that bind to C1s. Also provided are methods of producing the antibodies of the present disclosure, as well as uses of the provided antibodies and compositions for the treatment of C1s mediated diseases and disorders. ## Claims ### Claim 1 An antibody, or an antigen binding fragment thereof, wherein the antibody, or the antigen binding fragment thereof, comprises: a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 has the amino acid sequence of SEQ ID NO: 78; and a light chain variable region comprising light chain LCDR1, LCDR3, and LCDR3 sequences, wherein the LCDR1 has the amino acid sequence of SEQ ID NO: 64, the LCDR2 has the amino acid sequence of SEQ ID NO: 65, and the LCDR3 has the amino acid sequence of SEQ ID NO: 79. ### Claim 2 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 342. ### Claim 3 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 342. ### Claim 4 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 17. ### Claim 5 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 17. ### Claim 6 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 454. ### Claim 7 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 454. ### Claim 8 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 381. ### Claim 9 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, o wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 381. ### Claim 10 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, herein the antibody, or the antigen binding fragment thereof, comprises a heavy chain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 185. ### Claim 11 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 185. ### Claim 12 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the light chain variable region comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18. ### Claim 13 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 18. ### Claim 14 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises a light chain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 236. ### Claim 15 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises a light chain comprising the amino acid sequence of SEQ ID NO: 236. ### Claim 16 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 342, and the light chain variable region comprising the amino acid sequence of SEQ ID NO 18. ### Claim 17 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 381, and a light chain comprising the amino acid sequence of SEQ ID NO: 236. ### Claim 18 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, and the light chain variable region comprising the amino acid sequence of SEQ ID NO 18. ### Claim 19 (depends on 1) The antibody, or the antigen binding fragment thereof, of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 185, and a light chain comprising the amino acid sequence of SEQ ID NO: 236. ### Claim 20 (depends on 1) A pharmaceutical composition comprising the antibody, or the antigen binding fragment thereof, of claim 1, and a pharmaceutically acceptable excipient. ### Claim 21 (depends on 1) A method of treating a subject with Myasthenia Gravis, hemolysis, Cold Agglutinin Disease, Immune Thrombocytopenia (ITP), Glomerulopathies, Atypical Hemolytic uremic syndrome, antiphospholipid antibody syndrome, transplant rejection, Chronic inflammatory demyelinating polyneuropathy (CIDP), Multifocal motor neuropathy (MMN), Dermatomyositis, or Anti MAG neuropathy, the method comprising administering to the subject the antibody, or the antigen binding fragment thereof, of claim 1, or a pharmaceutical composition comprising the antibody, or the antigen binding fragment thereof, of claim 1. ### Claim 22 (depends on 21) The method of claim 21, wherein the subject is a subject with Myasthenia Gravis. ### Claim 23 (depends on 21) The method of claim 21, wherein the subject is a subject with Cold Agglutinin Disease. ### Claim 24 (depends on 21) The method of claim 21, wherein the subject is a subject with Chronic inflammatory demyelinating polyneuropathy (CIDP). ### Claim 25 (depends on 21) The method of claim 21, wherein the subject is a subject with Multifocal motor neuropathy (MMN).